CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and…
Read More
Revealed seven classes of promising novel drug candidates discovered using Enveric's Psybrary™ and PsyAI™ drug discovery and artificial intelligence (AI) platforms Launched business development campaign that resulted in the execution…
Read More
MindBio to develop the novel psilocin prodrug for neuropsychiatric indications utilizing microdosing to reduce or eliminate hallucinogenic impact of psychedelic compounds CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or…
Read More
Biotechnology licensee expected to progress methods targeting breast and other cancers using cannabinoids in combination with chemotherapeutic drugs CAMBRIDGE, Mass. - Enveric Biosciences, Inc (NASDAQ: ENVB), a biotechnology company dedicated…
Read More
Product Development Highlights: Selected neuroplastogen lead candidate EB-003, a potential first-in-class therapeutic option for addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations. Started IND-enabling preclinical activities for…
Read More
Second biotechnology company to potentially out-license novel compounds from Enveric's portfolio of assets with possible significant milestone payments and royalties CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the…
Read More
Patents extend compositional protection to proprietary compounds CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics…
Read More
Potentially significant milestone payments and execution fees if all development and sales criteria are met for all three agreements. CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"),…
Read More
Enveric continues focused investment advancing novel neuroplastogenic molecules for the treatment of mental health disorders CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated…
Read More
Novel compounds protected under Enveric's intellectual property portfolio provide potential licensing opportunities and non-dilutive revenue streams. CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company…
Read More
